Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 21 for:    brca | Open Studies | United States, Massachusetts
Previous Study | Return to List | Next Study

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Dana-Farber Cancer Institute
Sponsor:
Information provided by (Responsible Party):
Nadine Tung, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01670500
First received: August 16, 2012
Last updated: August 30, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2018
  Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)